Jun 2026 (Q2 FY26) — Aug 4, 2026
Palvella Therapeutics Q2 FY26 — NDA Submission Progress and Pipeline Expansion
Read the full callPalvella Therapeutics earnings: last reported Tue, 4 Aug 2026, for the quarter ended Jun 2026.
Reported
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | Quarterly, as filed | Quarter to Jun 2026 | Not in the filed figures for the quarter to jun 2026. No older figure is substituted. | ||
| Operating margin | Operating profit / revenue | Quarter to Jun 2026 | Not in the filed figures for the quarter to jun 2026. No older figure is substituted. | ||
| Net profit | -21.9 | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. The year-earlier figure was zero or a loss, so no percentage is shown. |
Price
1Y: $76.31 on 15 Oct 2025 → $120.3. High $158.13 (22 Sept 2026), low $70.43 (27 Oct 2025).
Overview
Call summaries
Palvella Therapeutics Q2 FY26 — NDA Submission Progress and Pipeline Expansion
Read the full callEvery analysed call
Financials
Net profit, year on year: −131% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 0 | — | — | — | — | — | — | — |
| Operating profit | -5 | -1 | -8 | -9 | -10 | -11 | -15 | -21 |
| Profit before tax | -7 | -4 | -8 | -9 | -11 | -13 | -16 | -22 |
| Tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net profit | -7 | -6 | -8 | -9 | -11 | -13 | -16 | -22 |
| EPS ($ per share) | -3.94 | — | -0.74 | -0.86 | -1.03 | — | -1.20 | -1.52 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reserves | -147 | -174 | -211 | -257 | -290 | -76 | -94 | -135 |
| Total liabilities | 101 | 90 | 74 | 103 | 68 | 11 | 26 | 32 |
| Fixed assets | 5 | 20 | 22 | 19 | 17 | 0 | — | — |
| Investments | 53 | 42 | 0 | 0 | 21 | 9 | — | 0 |
| Total assets | 141 | 141 | 105 | 154 | 95 | 8 | 88 | 60 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | -1 | -52 | -46 | -8 | -60 | -14 | -11 | -25 |
| Cash from investing | -9 | 10 | 39 | -1 | -21 | 12 | — | — |
| Cash from financing | 49 | 32 | 10 | 59 | 7 | 5 | 87 | -1 |
| Net cash flow | 37 | -13 | 8 | 47 | -79 | -9 | 76 | -26 |
| Capital expenditure | -2 | -2 | -3 | -1 | -1 | -0 | — | — |
| Free cash flow | -3 | -55 | -49 | -9 | -61 | -14 | — | — |
87 filings between Nov 19, 2025 and Oct 14, 2026.
Purchases
$850.0K
3 purchases by 2 insiders
Sales
$13.30M
60 sales by 3 insiders
98% filed under a 10b5-1 plan — scheduled in advance, not decided on the day
| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| JENKINS GEORGE M | $550.0K | $7.75M | Oct 14, 2026 |
| Goin Kathleen | — | $5.51M | Sep 16, 2026 |
| HERON ELAINE J | $300.0K | — | Feb 27, 2026 |
| KIRITSY CHRISTOPHER P | — | $49.1K | Sep 2, 2026 |
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Oct 14, 2026 | JENKINS GEORGE M Director | Sale 10b5-1 plan | 597 | $74.8K |
| Oct 14, 2026 | JENKINS GEORGE M Director | Sale 10b5-1 plan | 476 | $57.7K |
| Oct 14, 2026 | JENKINS GEORGE M Director | Sale 10b5-1 plan | 2,072 | $254.1K |
| Oct 14, 2026 | JENKINS GEORGE M Director | Sale 10b5-1 plan | 920 | $114.4K |
| Oct 14, 2026 | JENKINS GEORGE M Director | Sale 10b5-1 plan | 2,604 | $321.0K |
| Oct 14, 2026 | JENKINS GEORGE M Director | Sale 10b5-1 plan | 505 | $63.9K |
| Oct 13, 2026 | JENKINS GEORGE M Director | Sale 10b5-1 plan | 990 | $129.2K |
| Oct 13, 2026 | JENKINS GEORGE M Director | Sale 10b5-1 plan | 579 | $76.7K |
| Oct 13, 2026 | JENKINS GEORGE M Director | Sale 10b5-1 plan | 922 | $123.3K |
| Oct 13, 2026 | JENKINS GEORGE M Director | Sale 10b5-1 plan | 2,004 | $257.6K |
| Oct 13, 2026 | JENKINS GEORGE M Director | Sale 10b5-1 plan | 1,644 | $212.5K |
| Oct 13, 2026 | JENKINS GEORGE M Director | Sale 10b5-1 plan | 1,035 | $136.1K |
| Oct 12, 2026 | JENKINS GEORGE M Director | Sale 10b5-1 plan | 1,447 | $196.1K |
| Oct 12, 2026 | JENKINS GEORGE M Director | Sale 10b5-1 plan | 5,095 | $675.7K |
| Oct 12, 2026 | JENKINS GEORGE M Director | Sale 10b5-1 plan | 2,458 | $327.5K |
| Oct 12, 2026 | JENKINS GEORGE M Director | Sale 10b5-1 plan | 3,335 | $447.6K |
| Oct 12, 2026 | JENKINS GEORGE M Director | Sale 10b5-1 plan | 817 | $111.5K |
| Sep 16, 2026 | Goin Kathleen Chief Operating Officer | Sale 10b5-1 plan | 1,654 | $253.5K |
| Sep 16, 2026 | Goin Kathleen Chief Operating Officer | Sale 10b5-1 plan | 989 | $150.7K |
| Sep 16, 2026 | Goin Kathleen Chief Operating Officer | Sale 10b5-1 plan | 1,659 | $250.8K |
| Sep 16, 2026 | Goin Kathleen Chief Operating Officer | Option exercise 10b5-1 plan | 2,148 | $19.5K |
| Sep 16, 2026 | Goin Kathleen Chief Operating Officer | Option exercise 10b5-1 plan | 2,154 | $15.4K |
| Sep 15, 2026 | JENKINS GEORGE M Director | Sale 10b5-1 plan | 560 | $84.7K |
| Sep 15, 2026 | JENKINS GEORGE M Director | Sale 10b5-1 plan | 263 | $39.6K |
| Sep 15, 2026 | JENKINS GEORGE M Director | Sale 10b5-1 plan | 954 | $142.5K |
| Sep 14, 2026 | JENKINS GEORGE M Director | Sale 10b5-1 plan | 6,160 | $937.0K |
| Sep 14, 2026 | JENKINS GEORGE M Director | Sale 10b5-1 plan | 1,560 | $238.8K |
| Sep 14, 2026 | JENKINS GEORGE M Director | Sale 10b5-1 plan | 5,632 | $853.0K |
| Sep 11, 2026 | JENKINS GEORGE M Director | Sale 10b5-1 plan | 6,520 | $982.0K |
| Sep 11, 2026 | JENKINS GEORGE M Director | Sale 10b5-1 plan | 4,577 | $694.4K |
| Sep 11, 2026 | JENKINS GEORGE M Director | Sale 10b5-1 plan | 1,274 | $195.0K |
| Sep 2, 2026 | KIRITSY CHRISTOPHER P Director | Option exercise | 313 | $39.8K |
| Sep 2, 2026 | KIRITSY CHRISTOPHER P Director | Sale | 313 | $49.1K |
| Aug 19, 2026 | Goin Kathleen Chief Operating Officer | Sale 10b5-1 plan | 102 | $15.9K |
| Aug 19, 2026 | Goin Kathleen Chief Operating Officer | Sale 10b5-1 plan | 400 | $61.2K |
| Aug 19, 2026 | Goin Kathleen Chief Operating Officer | Option exercise 10b5-1 plan | 2,154 | $15.4K |
| Aug 19, 2026 | Goin Kathleen Chief Operating Officer | Sale 10b5-1 plan | 1,998 | $303.3K |
| Aug 19, 2026 | Goin Kathleen Chief Operating Officer | Sale 10b5-1 plan | 1,500 | $227.1K |
| Aug 19, 2026 | Goin Kathleen Chief Operating Officer | Option exercise 10b5-1 plan | 2,148 | $19.5K |
| Aug 19, 2026 | Goin Kathleen Chief Operating Officer | Sale 10b5-1 plan | 302 | $47.3K |
| Jul 15, 2026 | Goin Kathleen Chief Operating Officer | Sale 10b5-1 plan | 1,029 | $153.6K |
| Jul 15, 2026 | Goin Kathleen Chief Operating Officer | Option exercise 10b5-1 plan | 2,154 | $15.4K |
| Jul 15, 2026 | Goin Kathleen Chief Operating Officer | Option exercise 10b5-1 plan | 2,148 | $19.5K |
| Jul 15, 2026 | Goin Kathleen Chief Operating Officer | Sale 10b5-1 plan | 522 | $76.8K |
| Jul 15, 2026 | Goin Kathleen Chief Operating Officer | Sale 10b5-1 plan | 840 | $124.7K |
| Jul 15, 2026 | Goin Kathleen Chief Operating Officer | Sale 10b5-1 plan | 1,911 | $287.1K |
| Jun 17, 2026 | Goin Kathleen Chief Operating Officer | Option exercise 10b5-1 plan | 2,154 | $15.4K |
| Jun 17, 2026 | Goin Kathleen Chief Operating Officer | Option exercise 10b5-1 plan | 2,148 | $19.5K |
| Jun 17, 2026 | Goin Kathleen Chief Operating Officer | Sale 10b5-1 plan | 2,390 | $263.5K |
| Jun 17, 2026 | Goin Kathleen Chief Operating Officer | Sale 10b5-1 plan | 1,887 | $210.0K |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Free account. Everything above stays public.
Write why you follow PALVELLA THERAPEUTICS, INC. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading